JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Home・Akciju saraksts・Incyte Corp

Search

Incyte Corp

Slēgts

SektorsVeselības aprūpe

96.88 1.75

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

96.17

Max

97

Galvenie mērījumi
By Trading Economics
Ienākumi	-125M 299M
Pārdošana	141M 1.5B
P/E Sektora vidējais	14.932 67.147
Peļņas marža	19.861
Darbinieki	2,844
EBITDA	-92M 415M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+11.06% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 28. jūl.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-2.4B 19B
Iepriekšējā atvēršanas cena	95.13
Iepriekšējā slēgšanas cena	96.88

Ziņu noskaņojums

By Acuity

53%

47%

275 / 347 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

59.52 / 62.66 Atbalsts un pretestība

Incyte Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. maijs 23:47 UTC

Peļņas

National Australia Bank Warns of Economic Shock as 1st Half Profit Falls -- Update

2026. g. 3. maijs 22:35 UTC

Peļņas

National Australia Bank Holds Dividend Despite 19% 1st Half Profit Drop

2026. g. 3. maijs 23:39 UTC

Tirgus saruna

Gold Edge Higher Amid Signs of Resilience -- Market Talk

2026. g. 3. maijs 23:34 UTC

Tirgus saruna

Oil Declines Amid Mild Risk-on Sentiment -- Market Talk

2026. g. 3. maijs 23:32 UTC

Peļņas

National Australia Bank Warns of Economic Shock as 1H Profit Falls -- Update

2026. g. 3. maijs 23:30 UTC

Tirgus saruna

Nickel Industries Result Shows Power of Higher Prices -- Market Talk

2026. g. 3. maijs 23:20 UTC

Tirgus saruna

RBA Likely to Hike Rates; Guidance and Board Split Key -- Market Talk

2026. g. 3. maijs 23:16 UTC

Iegādes, apvienošanās, pārņemšana

GameStop Is Offering to Buy eBay for $56 Billion, CEO Ryan Cohen Says -- WSJ

2026. g. 3. maijs 22:57 UTC

Iegādes, apvienošanās, pārņemšana

GameStop Is Offering to Buy eBay For $56 Billion, CEO Ryan Cohen Says -- WSJ

2026. g. 3. maijs 22:57 UTC

Iegādes, apvienošanās, pārņemšana

GameStop Has Roughly 5% Stake in eBay, Cohen Says -- WSJ

2026. g. 3. maijs 22:57 UTC

Iegādes, apvienošanās, pārņemšana

GameStop Offering to Buy eBay for $125 a Share, or About $56 Billion, CEO Ryan Cohen Says -- WSJ

2026. g. 3. maijs 22:57 UTC

Iegādes, apvienošanās, pārņemšana

GameStop Is Prepared to Run Proxy Fight If eBay Isn't Receptive to a Deal, Cohen Says -- WSJ

2026. g. 3. maijs 22:57 UTC

Iegādes, apvienošanās, pārņemšana

GameStop Has Around $20 Billion in Debt Financing Committed From TD Bank, Cohen Says -- WSJ

2026. g. 3. maijs 22:45 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 3. maijs 22:45 UTC

Tirgus saruna

Low-Cost Miners in Spotlight Amid High Energy Prices -- Market Talk

2026. g. 3. maijs 22:20 UTC

Peļņas

National Australia Bank Holds Dividend Despite 19% 1H Profit Drop

2026. g. 3. maijs 22:08 UTC

Peļņas

NAB's 1H Included Previously Announced A$1.35B Software Amortization Charge>NAB.AU

2026. g. 3. maijs 22:05 UTC

Peļņas

NAB 1H Net Interest Income A$9.16B Vs. A$8.445B>NAB.AU

2026. g. 3. maijs 22:05 UTC

Peļņas

NAB 1H Credit Impairment Charge A$706M Vs. A$348M>NAB.AU

2026. g. 3. maijs 22:05 UTC

Peļņas

NAB 1H Operating Expenses A$5.02B Vs. A$4.81B>NAB.AU

2026. g. 3. maijs 22:04 UTC

Peļņas

NAB 1H Net Interest Margin 1.81%>NAB.AU>NAB.AU

2026. g. 3. maijs 22:03 UTC

Peļņas

NAB 1H Cash Return on Equity Ex-Large Notable Items 11.6%>NAB.AU

2026. g. 3. maijs 22:03 UTC

Peļņas

NAB 1H Cash Return on Equity 8.5%>NAB.AU

2026. g. 3. maijs 22:02 UTC

Peļņas

NAB 1H CET1 Capital Ratio 11.65% Vs. 12.01%>NAB.AU

2026. g. 3. maijs 22:02 UTC

Peļņas

NAB 1H Cash Earnings A$2.64B>NAB.AU

2026. g. 3. maijs 22:02 UTC

Peļņas

NAB 1H Cash Earnings Ex-Notable Items A$3.59B Vs. A$3.58B>NAB.AU

2026. g. 3. maijs 22:01 UTC

Peļņas

National Australia Bank Keeps Dividend at A$0.85 >NAB.AU

2026. g. 3. maijs 22:01 UTC

Peļņas

National Australia Bank 1H Rev A$11.16B Vs. A$10.28B >NAB.AU

2026. g. 3. maijs 22:01 UTC

Peļņas

National Australia Bank 1H Net A$2.75B Vs. Net A$3.41B >NAB.AU

2026. g. 3. maijs 15:06 UTC

Peļņas

Berkshire's Greg Abel Marks His First Annual Meeting as CEO. We'd Give Him a B-Plus. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Incyte Corp Prognoze

Cenas mērķis

By TipRanks

11.06% augšup

Prognoze 12 mēnešiem

Vidējais 107.63 USD 11.06%

Augstākais 135 USD

Zemākais 75 USD

Pamatojoties uz 18 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Incyte Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

18 ratings

7

Pirkt

10

Turēt

1

Pārdot

Pamatojoties uz 18 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Incyte Corp — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

59.52 / 62.66Atbalsts un pretestība

Bullish events outweigh bearish events.

All events are bearish.

All events are bearish.

Noskaņojums

By Acuity

275 / 347 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation

Citi krājumi no sektora

JNJ

Johnson and Johnson

227.46

UNH

UnitedHealth Group Inc

369.01

TMO

Thermo Fisher Scientific Inc

469.28

ISRG

Intuitive Surgical Inc

457.59

ABT

Abbott Laboratories

89.51

Live chat